MYNZ Valuation

Mainz Biomed NV

Add to Watchlist

Advanced Chart

1.650

-0.07(-4.070%)1D

Overview
Forecast
Valuation
Earnings

MYNZ Relative Valuation

MYNZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MYNZ is overvalued; if below, it's undervalued.

Historical Valuation

Mainz Biomed NV (MYNZ) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.45 is considered Undervalued compared with the five-year average of -2.70. The fair price of Mainz Biomed NV (MYNZ) is between 3.69 to 4.96 according to relative valuation methord. Compared to the current price of 1.65 USD , Mainz Biomed NV is Undervalued By 55.24%.

Relative Value

Fair Zone

3.69-4.96

Current Price：1.65

55.24%

Undervalued

-0.44

Trailing

Forward

0.00

EV/EBITDA

Mainz Biomed NV. (MYNZ) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.14

EV/EBIT

Mainz Biomed NV. (MYNZ) has a current EV/EBIT of -0.14. The 5-year average EV/EBIT is -2.30. The thresholds are as follows: Strongly Undervalued below -7.02, Undervalued between -7.02 and -4.66, Fairly Valued between 0.07 and -4.66, Overvalued between 0.07 and 2.43, and Strongly Overvalued above 2.43. The current Forward EV/EBIT of -0.14 falls within the Historic Trend Line -Fairly Valued range.

5.45

Mainz Biomed NV. (MYNZ) has a current PS of 5.45. The 5-year average PS is 58.98. The thresholds are as follows: Strongly Undervalued below -104.48, Undervalued between -104.48 and -22.75, Fairly Valued between 140.70 and -22.75, Overvalued between 140.70 and 222.43, and Strongly Overvalued above 222.43. The current Forward PS of 5.45 falls within the Historic Trend Line -Fairly Valued range.

-0.10

P/OCF

Mainz Biomed NV. (MYNZ) has a current P/OCF of -0.10. The 5-year average P/OCF is -3.16. The thresholds are as follows: Strongly Undervalued below -12.71, Undervalued between -12.71 and -7.94, Fairly Valued between 1.61 and -7.94, Overvalued between 1.61 and 6.38, and Strongly Overvalued above 6.38. The current Forward P/OCF of -0.10 falls within the Historic Trend Line -Fairly Valued range.

-0.28

P/FCF

Mainz Biomed NV. (MYNZ) has a current P/FCF of -0.28. The 5-year average P/FCF is -0.12. The thresholds are as follows: Strongly Undervalued below -0.50, Undervalued between -0.50 and -0.31, Fairly Valued between 0.07 and -0.31, Overvalued between 0.07 and 0.26, and Strongly Overvalued above 0.26. The current Forward P/FCF of -0.28 falls within the Historic Trend Line -Fairly Valued range.

Mainz Biomed NV (MYNZ) has a current Price-to-Book (P/B) ratio of 0.66. Compared to its 3-year average P/B ratio of 4.22 , the current P/B ratio is approximately -84.35% higher. Relative to its 5-year average P/B ratio of 6.16, the current P/B ratio is about -89.29% higher. Mainz Biomed NV (MYNZ) has a Forward Free Cash Flow (FCF) yield of approximately -285.64%. Compared to its 3-year average FCF yield of -142.08%, the current FCF yield is approximately 101.04% lower. Relative to its 5-year average FCF yield of -112.28% , the current FCF yield is about 154.41% lower.

0.66

P/B

Median3y

4.22

Median5y

6.16

-285.64

FCF Yield

Median3y

-142.08

Median5y

-112.28

Competitors Valuation Multiple

The average P/S ratio for MYNZ's competitors is 39.15, providing a benchmark for relative valuation. Mainz Biomed NV Corp (MYNZ) exhibits a P/S ratio of 5.45, which is -86.08% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Avalon Globocare Corp

Transcode Therapeutics Inc

Kazia Therapeutics Ltd

Performance Decomposition

Market capitalization of MYNZ increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MYNZ in the past 1 year is driven by Unknown.